Duloxetine versus placebo in the treatment of stress urinary incontinence.
about
Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adultsNeurophysiology of lower urinary tract function and dysfunctionDuloxetine in the treatment of stress urinary incontinenceStress urinary incontinence in women.Duloxetine compared with placebo for treating women with symptoms of overactive bladder.Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trialStress incontinence.Neural control of the lower urinary tract: peripheral and spinal mechanismsUrinary incontinence in the elderly: part 3 of a series of articles on incontinenceNeural control of the female urethral and anal rhabdosphincters and pelvic floor muscles.Alpha2-adrenoceptor blockade potentiates the effect of duloxetine on sneeze induced urethral continence reflex in rats.The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis.Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports.Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary IncontinenceDuloxetine in the treatment of major psychiatric and neuropathic disorders.Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence.Lower urinary tract disease: what are we trying to treat and in whom?Nursing management of stress urinary incontinence in women.Current management of stress urinary incontinence.Clinical practice guidelines for the initial management of urinary incontinence in women: a European-focused review.Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.Clinical practice guidelines on the initial assessment and treatment of urinary incontinence in women: a US focused review.Duloxetine: a new approach for treating stress urinary incontinence.Neurobiology of stress urinary incontinence: new insights and implications for treatment.Safety and adverse event profile of duloxetine.Coining a new term-Urovesicology: advancing towards a mechanistic understanding of bladder symptoms.Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression.Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice.An overview of stress urinary incontinence treatment in women.The treatment of urinary incontinence with Duloxetine.Urodynamic leak point pressures weakly correlate with subjective urinary incontinence severity.Current issues in the management of female urinary incontinence.Update on duloxetine for the management of stress urinary incontinence.Stem cells for stress urinary incontinence: the adipose promise.The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats.Treatment of mixed urinary incontinence.Duloxetine Treatment of Stress Urinary Incontinence in Women Does Not Induce Mania or Hypomania.Neurophysiology and therapeutic receptor targets for stress urinary incontinence.Management of mixed urinary incontinence.
P2860
Q24246568-8E47C967-278D-4FD7-B217-53503428A50FQ24550931-4FF639F6-FB06-4E83-ADDE-9D725CB557FAQ24680252-F8C19353-44E3-4A62-8783-7617FB24D627Q30433747-201D2050-D0F3-4DC0-9D64-2192ED56187BQ30443662-F5756BF9-049A-46E6-B9CD-A8E277B4A5F6Q33316575-3C3432DA-636E-464D-A5C5-8B6846F3B85FQ34010677-F8984051-AAC1-453C-9C5B-54341F4A34F2Q34020395-90CF92D9-1F70-4F7E-B032-788B059C8C6EQ34078299-AB7F49EA-481C-4BA7-94CB-BCEBE007FBFCQ34085595-F4243171-3F79-493B-A3EB-C192FF9CE8CBQ34158357-7C42F9D7-3C84-4FAD-8A76-10A8AF3BA12BQ34333544-BC73FCDB-8395-4139-B86F-A14D60052BC0Q34552333-291A78F4-6FFD-4A12-9FD9-FFB90164372CQ34769139-45034CC3-E292-481E-8035-0D3B42DB6A6AQ34770302-127FA65F-C847-4340-8681-863CB51C31D3Q35207634-25C8887A-4BFD-4B39-B166-41180EEB3552Q35545715-BE38E2FE-9E4F-4595-AB57-481873FF4BBCQ35668828-BFF13D9A-33F3-481E-B902-7113FBB63716Q35771615-9E4DE659-A3AF-4BC3-8DA3-B090F9DCA490Q35771620-9E12681D-C01E-46EF-A6B9-D01E89262B4FQ35826128-A746E959-76FD-4830-BE9A-567965127CCFQ35859633-4D250880-812B-4407-9DBB-A474BB651480Q35859638-C7B301DC-E299-401F-A731-F42B13AE9B07Q36290129-6BA62A39-7A0D-4C34-83EE-5DFABA726C13Q36299961-C7865709-B848-4AC7-B6A5-D77CC59480D0Q36463541-BF64018E-C27C-47DA-8EBA-EDE8355F02A2Q36489025-0BD83557-391C-4A2F-A596-231791EEC3CBQ36729973-6D392047-BC68-48C7-BBDA-0015F1DCC5E4Q36921864-B12C62D1-127B-4BCE-A576-1D7B2D0083CDQ37130272-91773DC7-5534-4802-AA6D-9E3805C9140DQ37172606-C26DF7D0-713C-4684-8DF5-B0B66319C3EAQ37192368-70D09B9E-28E4-433E-A984-36E82044A2B2Q37199879-FA4F7253-B34A-4DA8-B790-F8DBFF3D3495Q37334953-78597850-D7BF-4082-8EBA-663BB8974DBFQ37360532-0A965D63-4C7A-4C7D-86BE-6CB0155954CEQ37440147-F846517A-626F-42CE-9D25-409F5A9CA230Q37579064-196A1862-08D9-437D-9D4B-E0AEF7C159DEQ37708622-36B49425-1D5A-4E0E-9FA8-2D1FDF675631Q37992131-471D46F8-1911-4A83-86AE-7665985F667DQ38039168-5B36499F-92E9-4EED-994F-39AF7C4CDE7E
P2860
Duloxetine versus placebo in the treatment of stress urinary incontinence.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Duloxetine versus placebo in the treatment of stress urinary incontinence.
@en
Duloxetine versus placebo in the treatment of stress urinary incontinence.
@nl
type
label
Duloxetine versus placebo in the treatment of stress urinary incontinence.
@en
Duloxetine versus placebo in the treatment of stress urinary incontinence.
@nl
prefLabel
Duloxetine versus placebo in the treatment of stress urinary incontinence.
@en
Duloxetine versus placebo in the treatment of stress urinary incontinence.
@nl
P2093
P356
P1476
Duloxetine versus placebo in the treatment of stress urinary incontinence.
@en
P2093
Duloxetine Urinary Incontinence Study Group
Ilker Yalcin
Norman R Zinner
Peggy A Norton
Richard C Bump
P356
10.1067/MOB.2002.124840
P407
P577
2002-07-01T00:00:00Z